Plant Name: Trigonostemon reidioides
Taxonomic Information:
Plant ID: NPO17790
Plant Latin Name: Trigonostemon reidioides
Taxonomy Genus: Trigonostemon
Taxonomy Family: Euphorbiaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
358060-1
Used in Medicines:
Country/Region:
ThailandTraditional Medicine System:
Geographical Distribution:
Thailand; Vietnam; Myanmar; Cambodia; Laos
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CCR6; TSHR; | |
| GCGR; | |
| ADRA1B; ADRA1A; | |
| ACHE; | |
| AURKB; AURKA; KDR; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Peptide receptor (family A GPCR) | CCR6 | C-C chemokine receptor type 6 | P51684 | CHEMBL4423 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family B GPCR) | GCGR | Glucagon receptor | P47871 | CHEMBL1985 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Small molecule receptor (family A GPCR) | ADRA1B | Alpha-1b adrenergic receptor | P35368 | CHEMBL232 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.185E-07 | 1.670E-03 | CYP19A1, CYP1A1, CYP1B1 |
| MF | GO:0060089; molecular transducer activity | GO:0004937; alpha1-adrenergic receptor activity | 1.254E-06 | 2.715E-03 | ADRA1A, ADRA1B |
| BP | GO:0065007; biological regulation | GO:0001994; norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure | 2.507E-06 | 4.460E-03 | ADRA1A, ADRA1B |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.325E-06 | 4.826E-03 | CYP19A1, CYP1A1, CYP1B1 |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 4.177E-06 | 5.350E-03 | AURKA, AURKB |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 6.262E-06 | 6.494E-03 | AURKA, AURKB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.131E-06 | 1.167E-04 | CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.484E-06 | 1.167E-04 | CYP1A1, CYP1B1, CYP19A1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.333E-05 | 2.800E-04 | GCGR, ADRA1B, ADRA1A, TSHR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 3.000E-04 | 2.700E-03 | CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.986E-04 | 7.190E-03 | CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04970 | Salivary secretion | 1.479E-03 | 7.608E-03 | ADRA1B, ADRA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.258E-03 | 7.547E-03 | CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | GCGR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1A; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; ADRA1B; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; ACHE; |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GCGR; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | ADRA1B; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AURKA; KDR; ACHE; |
| C00-D49: Neoplasms | Liver cancer | C22 | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; ACHE; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA1B; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | KDR; CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | GCGR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Exogenous obesity | E66 | ADRA1B; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | GCGR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | GCGR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | GCGR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA1A; ACHE; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AURKA; AURKB; KDR; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; AURKB; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
